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ABSTRACT 
Patients with diabetes (DM) experience higher rates of in-stent restenosis and 
therefore greater benefit from drug eluting stent (DES) implant at the time of percutaneous 
coronary intervention (PCI). DES stent implantation necessitates prolonged dual anti-platelet 
therapy (DAPT). While DAPT reduces the risk of ischemic events post-PCI, it also increases 
the risk for bleeding. Whether long-term rates of bleeding differ among patients with and 
without DM receiving DAPT in real-world practice is unknown.  
Among patients who underwent PCI and were maintained on DAPT for 1 year in a 
multicenter US PCI registry, OPS/PRISM, we assessed patient-reported bleeding (defined 
according to the Bleeding Academic Research Consortium, BARC) over the year following 
PCI in patients with and without DM. Bleeding assessments were conducted by a study 
coordinator at index hospitalization (baseline) and at 1, 6 and 12 months following discharge. 
Multivariable logistic regression was used to evaluate the association of DM with bleeding 
during follow-up. In a sensitivity analysis, we excluded bruising from BARC-defined 
bleeding events.  Covariates included in the model were selected a priori and were abstracted 
from the medical record by study coordinators. Covariates included demographic (e.g. age, 
insurance status) and clinical (e.g. medical history, procedural indication) variables.  
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Among 2270 PCI patients (mean age 64, 72% male, 54% ACS), 32.6% had DM. In 
unadjusted analyses, patients with DM had fewer BARC ≥1 bleeding events over the year 
following PCI (DM vs no DM: BARC ≥1: 77.7% vs 87.6%, p<0.001; BARC ≥ 2: 4.5% vs 
5.3%, p=0.41). After adjusting for demographic and clinical factors, patients with DM had 
lower odds of BARC ≥1 bleeding during follow-up (odds ratio [OR] 0.52, 95% CI 0.39-0.68, 
p<0.001 vs. no DM). This decreased odds of bleeding persisted after removing bruising from 
the endpoint definition (OR 0.77, 95% CI 0.62-0.96). 
In a real-world PCI registry, patients with DM experienced lower bleeding on DAPT 
than those without DM. As patients with DM also derive greater ischemic benefit from DES, 
which requires prolonged DAPT, our findings suggest that the balance between benefit and 
risk of this therapeutic approach is even more favorable in patients with DM than previously 
considered.  
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CHAPTER 1 
INTRODUCTION 
Percutaneous coronary intervention (PCI) is a cardiovascular procedure indicated for 
treatment of significant coronary stenosis and typically involves stent placement in a large 
coronary artery. This procedure may be indicated in an acute setting, such as during an acute 
coronary syndrome, or heart attack.1 The procedure may also be indicated for patients with 
refractory angina, or cardiac-type chest pain, which has not responded to optimal medical 
management with cardiac medications.2 The volume of PCIs has steadily risen over the past 
several decades.3  
Bleeding events following PCI are common and are associated with an increased cost 
and increased short- and long-term risk of morbidity and mortality.4,5 The prevalence and 
prognosis of bleeding in the first year after PCI was recently described by Amin et al, who 
reported that 37.5% of patients reported nuisance bleeding, which was associated with worse 
quality of life.6  
There are two stent type categories used in PCI procedures: the drug eluting (DES) 
and the bare metal stent (BMS) (Table 1). The DES is a more contemporary device 
consisting of a metallic stent backbone, antiproliferative drug, and a polymer that serves as 
the vehicle for drug delivery and drug release.7 On the other hand, the BMS is composed of a 
metallic design without an embedded antiproliferative drug.7 Prior studies exploring the 
efficacy of DES versus BMS have concluded that DES use is preferred because of improved 
ischemic outcomes and decreased need for repeat revascularization as compared to BMS 
use.8 In addition to efficacy considerations, long term bleeding risk estimation may inform 
whether or not a DES with prolonged DAPT (and potentially higher risk of bleeding) versus 
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a BMS with a need for shorter duration post procedural anti-platelet therapy (and a lower risk 
of bleeding) is to be preferred.  However, other considerations like the likelihood of in-stent 
restenosis must be simultaneously considered at the time of PCI. 
Diabetes mellitus (DM) may be such a factor that needs to be taken into account 
when choosing the stent type in PCI. Patients with DM constitute approximately thirty 
percent of all patients undergoing coronary revascularization, including PCI and coronary 
artery bypass grafting.9 More specifically, patients with DM constitute approximately twenty 
five percent of all patients undergoing PCI in large clinical trials.10,11 There is reason to 
believe that patients with diabetes, as a result of increased platelet aggregation and 
hyporesponse to anti platelet medication, may experience bleeding at different rates than 
patients without diabetes. Prior studies exploring in- stent restenosis following PCI with drug 
eluting stent (DES) suggest that patients with DM experience higher rates of in-stent 
restenosis and therefore greater net benefit from DES (as compared with BMS) implant at the 
time of PCI.10,12-14 As a result, the American Heart Association provides a Class I (highest 
available) recommendation that patients with DM receive prolonged DAPT following DES 
placement to decrease risk of late stent thrombosis.1,15 While DAPT reduces the risk of 
ischemic events post-PCI, it is known to also increase the risk for bleeding in patients 
undergoing elective PCI, as well as those undergoing PCI for an indication of acute coronary 
syndrome.16-18 It is unknown, however, whether this risk of bleeding would be generalizable 
to the subgroup of coronary artery disease patients who have DM. Having such information 
would help to inform clinical decisions regarding duration of DAPT prescription, in this 
particular risk group. 
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There is reason to believe that not only due to restenosis risk, but also due to bleeding 
risk, choosing a DES for patients with DM who undergo PCI would be beneficial. In large 
acute coronary syndrome clinical trials exploring ischemic outcomes of patients on DAPT 
following PCI, such as Trial to Assess Improvement in Therapeutic Outcomes by Optimizing 
Platelet Inhibition with Prasugrel—Thrombolysis in Myocardial Infarction (TRITON TIMI-
38), pre-specified subgroup analyses of patients with DM revealed that these patients derived 
a greater benefit, and specifically a lower bleeding risk, from more aggressive platelet 
inhibition after acute coronary syndrome as compared with patients without DM.19 In 
TRITON TIMI-38, visits to assess clinical end points and adverse events, including bleeding, 
were at hospital discharge, day 30 (28-35 days), day 90 (±2 weeks), and every 90 days (±2 
weeks) thereafter for up to 15 months.19 By 15 month follow up, patients with DM 
experienced all cause death, non-fatal myocardial infarction, non-fatal stroke and non-fatal 
major bleeding (14.6% vs. 19.2%, p=0.001)20 
This greater net benefit is hypothesized to be due to patients with DM experiencing 
greater platelet reactivity.21 While patients in these trials underwent emergent or urgent PCI 
for an indication of acute coronary syndrome, it is unknown whether patients with DM incur 
better bleeding outcomes (versus patients without DM) on prolonged DAPT following PCI 
for a broader set of indications. It is unknown whether or not long-term bleeding rates differ 
among patients with and without DM receiving prolonged DAPT (Figure 1). We aim to 
address this study question in the Outcomes of PCI Study-Personalized Risk Information 
Services Manager (OPS-PRISM) registry, a study including patients undergoing PCI for 
emergency and elective indications. Accordingly, our first aim is to describe the incidence of 
bleeding following PCI in patients with and without DM. Our second aim is to evaluate the 
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independent association of DM with bleeding events, adjusting for relevant clinical and 
socioeconomic factors. Our final aim is to examine bleeding outcomes according to 
indication for PCI (i.e. acute coronary syndrome [emergent or urgent] versus refractory 
angina management [elective]). As an exploratory analysis, we plan to examine raw rates of 
DAPT discontinuance in patients with and without DM to ensure that differing rates of 
DAPT discontinuance do not contribute to differing rates of bleeding following PCI.  
  
 
 
5 
 
Table 1. Characteristics of BMS vs. DES stent use during PCI  
Bare metal stent Drug eluting stent 
DAPT duration: 
DAPT recommended for at least 
1 month and preferably 1 year 
following PCI 
DAPT duration: 
DAPT recommended for at least 
1 year following PCI 
Benefits: 
May be preferred if patient has 
history of bleeding problems, 
planned elective surgery, 
medication adherence issues 
• Lower cost 
• Shorter duration of 
DAPT use 
Benefits: 
May be preferred if patient able 
to adhere to longer duration of 
antiplatelet therapy and thus 
may therein derive greater 
benefit from DES (lower risk of 
in stent restenosis, less risk of 
resultant repeat 
revascularization) 
Risks: 
Associated with higher risk of 
in stent restenosis 
 
Risks: 
Associated with longer DAPT 
duration, thus: 
• Higher cost 
• Associated with higher 
risk of bleeding 
 
  
 
 
6 
 
 
  
Figure 1. Knowledge Gaps Regarding Patients with Diabetes and Coronary Artery Disease 
Prescribed Dual Anti platelet Therapy 
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CHAPTER 2 
METHODOLOGY 
Study Design and Participants 
The Patient Risk Information Services Manager (PRISM) and Outcomes of PCI Study (OPS) 
prospective observational registries were used as the sources of data for this study.  These are 
ideal databases to answer our research questions as they contain de-identified data for of 
three thousand coronary artery disease patients available at Saint Luke’s Hospital in Kansas 
City, MO. From May 26, 2009 to October 21, 2011. Overall, 3299 PCI patients from 10 U.S. 
hospitals were enrolled in PRISM (Supplemental Table 1). PRISM follow up assessments 
were conducted at 1,6 and 12 months following index PCI. The Outcomes of PCI Study 
(OPS) registry was a very similar registry to that of PRISM, with identical enrolment criteria. 
However, OPS enrolled 1901 patients between April 2009 and October 2011, and follow up 
assessments were conducted at 6 and 12 months following index PCI. The four sites 
participating in the OPS registry also participated in the PRISM registry (Mid America Heart 
Institute, Yale, Integris and the Mayo Clinic). The patients were scheduled for urgent PCI for 
management of acute coronary syndrome or elective PCI for persistent angina. Patients were 
recruited by the study coordinators at each site. Any patient who had a PCI was approached 
during their hospital stay post procedure. Notably, patients excluded from analysis were 
those not discharged on a thienopyridine or aspirin following index PCI. Patients who were 
not on DAPT at their 12-month assessment and those without a 12 month assessment 
available were also excluded from the final cohort (Figure 4). Regarding our follow up 
procedure, three experienced clinical research assistants at the Mid America Heart Institute 
made all of the follow up phone calls. Follow up interviews were largely conducted by phone 
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(Figure 2). Occasionally, an interview would be mailed, but these comprised a small 
percentage of our overall follow up responses. Data that were not derived directly from 
patient questionnaires, including chart-abstracted data, were obtained by study 
coordinators/nurses who entered abstracted data into Velos at each site. Velos is an internet-
based clinical research platform used for data entry and application. 
Procedural data from all PCIs performed during the study period were entered into a 
procedural case report form by the study coordinator at each site. The PCI case report form 
collected information including pre procedural medications, indication for PCI (arrhythmia 
management, preoperative non-cardiac surgery, congestive heart failure, staged intervention, 
stable coronary artery disease, unstable angina, non ST segment elevation myocardial 
infarction, ST segment elevation myocardial infarction), clinical evaluation pre procedurally, 
coronary vessel anatomy (native and graft vessel distribution), and percentage of coronary 
stenosis as estimated by the operator or adjunctive imaging/procedural modalities such as 
intravascular ultrasound or fractional flow reserve. Each participating site obtained 
Institutional Research Board approval, and all patients provided informed consent for 
baseline and follow up assessments.  
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Figure 2. Data collected at baseline and at 1, 6 and 12 month follow up interviews  
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Measures of Follow-Up Bleeding Data 
Within the OPS/PRISM registry data collection process, bleeding events were defined 
according to standard National Cardiovascular Data Registry definitions (access site bleeding 
with a hematoma >10 cm for femoral, >5 cm for brachial and >2 cm for radial access). 
Additionally, retroperitoneal, gastrointestinal, genitourinary bleeding requiring a transfusion, 
prolonged hospitalizations or hemoglobin drop of greater than 3 g/dL were prospectively 
collected as bleeding events. For our observational study, bleeding events were defined 
according to the Bleeding Academic Research Consortium (BARC) guidelines. Based on the 
BARC classification system, bleeding event severity is graded zero to five, with zero 
representing no bleeding and five representing fatal bleeding22(Table 3). Of note, we 
interpreted BARC 1 bleeding events to include bruising events and subsequently did a 
sensitivity analysis excluding self-reported bruising events (BARC ≥1 minus bruising).   
 As part of the OPS/PRISM study, patients were asked to report interval 
hospitalizations since their last study contact during the follow-up interviews. At each follow 
up interview, patients were asked whether they had experienced easy bruising, easy bleeding, 
occasional nose or gum bleed or serious bleeding since their last interview. If any of these 
bruising or bleeding outcomes were reported, a follow up question asked patients what they 
did about this bruising or bleeding. Choices included “didn’t tell any doctor”, “told doctor, 
but no treatment”, “doctor stopped a medicine or switched to another medicine”, “treated 
with transfusion”, or “treated by hospitalization”. Patients had the option of selecting all 
answer choices that applied. All patients were required to have a 12-month follow up 
assessment for the purposes of the primary analysis. Most patients had at least one additional 
assessment (most commonly at 6 months post index PCI). If a particular patient reported 
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more than one bleeding event during the follow up period, we included the most severe self-
reported bleeding episode for this analysis. Diabetes was defined as a diagnosis of type 1 or 
type 2 DM derived from baseline chart abstraction.  
Patient characteristics, including demographic (age, gender, ethnicity), 
socioeconomic (insurance status [presence or absence of medication insurance, medical 
insurance – any vs. none], avoidance of care due to cost in the past year, level of education 
[high school graduate versus not], marital status [married vs. unmarried]), and clinical (body 
mass index, kidney disease status, platelet count before PCI procedure, history of bleeding 
problems, baseline and nadir hemoglobin, blood transfusion status, history of lung disease, 
heart failure, acute coronary syndrome status, prior PCI, anticoagulation medication status, 
bleeding in the hospital, drug eluting stent placement) were compared at baseline.  
For multivariable adjustment, the following covariates were used: age, gender, race, 
body mass index, history of chronic kidney disease, acute coronary syndrome at time of 
presentation, heart failure and chronic lung disease, history of prior PCI, history of 
myocardial infarction, bleeding and/or transfusion during index hospitalization, and index 
PCI admission lab values including platelet count and nadir hemoglobin. We selected 
covariates to be included in the multivariable model a priori. These were based on prior 
literature review and clinical judgment of variables that may confound the association 
between bleeding and DM status, and included age23, gender24, ethnicity, platelet count, BMI, 
history of chronic kidney disease25, history of chronic lung disease, anticoagulation at 
discharge, placement of drug eluting stent, anemia, bleeding, and transfusion during index 
hospitalization23. We also adjusted for a history of bleeding problems, heart failure, history of 
PCI, and history of acute coronary syndrome26. 
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Statistical Analysis 
Baseline characteristics, including all demographic, socioeconomic, and clinical 
factors were compared between patients with vs. without DM using Chi square test for 
categorical variables and Mann-Whitney U test for continuous variables as the continuous 
variables were not parametrically distributed.  
 The incidence of bleeding over the year following index PCI, as assessed by a BARC 
score ≥1, was compared between groups at each follow-up time point using the Chi square 
test. Assumptions of logistic modeling were met, including an adequate sample size, lack of 
multicollinearity among predictor variables, and lack of unexplained outliers. Accordingly, a 
multivariable logistic regression model was used to assess the independent association 
between DM status and bleeding outcomes over the year following index PCI.  
Subsequently, we performed a sensitivity analysis to explore bleeding incidence at 
follow up when excluding bruising in the definition of bleeding (i.e. BARC ≥1 minus 
bruising as the primary outcome).  This analysis was considered informative as healthcare 
providers rarely recommend antiplatelet therapy discontinuation as a consequence of 
bruising, which is a common patient concern while on antiplatelet therapy. Because we 
included bruising within our initial definition of a BARC ≥1 bleeding event, it was important 
to further explore whether removing the commonly reported bruising from outcome 
definition would change our primary result. Were the results to remain largely unchanged 
following this sensitivity analysis, this would further support the clinical actionability of our 
results by demonstrating that pure bleeding outcomes (without bruising included in the 
definition) are still different in patients with and without DM.  
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Further, we completed an analysis which assessed bleeding rates (BARC ≥1) at 1, 6 
and 12 months following index PCI, including all patients discharged on DAPT. This  
analysis was performed because in the main model, we included patients who we required by 
our inclusion criteria to have reported taking 1 year of DAPT. Patients with DM are more 
likely to receive drug-eluting stent at time of PCI (and thus more likely to be on DAPT for 1 
year). Non-diabetic and other patients who are perceived to have high bleeding risk by the 
PCI physician usually get bare metal stent placement, necessitating only 1 month of DAPT. 
Thus our main model had the potential problem of excluding those at higher risk of 
bleeding.  To ensure that we did not dilute our results because of our methodological 
approach, we performed this analysis to look at rates of bleeding between patients with and 
without DM so as to evaluate patients who receive DAPT for less than 1 year (and may have 
baseline higher bleeding risk). If results of the bleeding outcomes at 1 and 6 months are 
similar from the results of our main model, that would further support the impact of DM on 
bleeding outcomes, regardless of perceived baseline bleeding risk.  
Lastly, to further exclude the possibility that bleeding differences found were in part 
explained by different antiplatelet therapy discontinuance rates, we analyzed discontinuance 
between patients with and without DM who were discharged on DAPT. 
In the original dataset, missing baseline data (mean number of missing items per 
patient=0.17) were imputed using IVEware (Imputation and Variance Estimation Software; 
University of Michigan's Survey Research Center, Institute for Social Research, Ann Arbor, 
MI). Little’s MCAR test was significant, suggesting that data were not missing completely at 
random. Single imputation was used to account for missing variables, as the rate of missing 
data for any individual variable was <10%. Because the baseline characteristics of patients 
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who did and did not have follow up data at 12 months were statistically different, we 
evaluated the effect of missingness on bleeding outcomes and found that the Cohen’s d was 
small for each of the significantly different baseline characteristics. As the effect was small 
(small effect size considered to be <0.1), we deferred further analyses of missingness.  
All analyses were conducted using SPSS Statistics 22, and statistical significance was 
determined by a 2-sided p-value of <0.05.  
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CHAPTER 3 
RESULTS 
Study Population 
Of 3299 patients from 10 U.S. sites (Supplemental Table A-3) enrolled in the 
OPS/PRISM registry, we excluded 135 (4.1%) patients because they were not discharged on 
a thienopyridine or aspirin. We also excluded 412 patients (13.0%) who did not report taking 
TPD or aspirin by the one year follow up interview and 482 patients (15.2%) who did not 
have a 12 month follow up assessment. Our final analytic cohort consisted of 2270 patients 
(Figure 4).  Patients who were missing 12 month outcomes data were more likely to be 
younger, non-white race, smokers, and of lower socioeconomic status compared with those 
in the analytic cohort (Supplemental Table 3) In addition, patients with missing data were 
less likely to be treated with drug eluting stent, had lower hemoglobin levels, and were more 
likely to report bleeding issues at baseline.  
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Figure 3.  Flow chart of analytic cohort in the OPS-PRISM percutaneous intervention 
registries 
Abbreviations: PCI: percutaneous intervention; ACS: acute coronary syndrome; TPD: thienopyridine; ASA: 
aspirin 
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Baseline Characteristics 
Among 2270 patients (54% with acute coronary syndrome) who were discharged and 
maintained on DAPT for one year following index PCI, 737 (32.5%) had DM. The baseline 
demographic and clinical characteristics of patients with vs. without DM are shown in Table 
A-1. Patients with DM were more commonly female (31.9% vs. 25.7%), non-white (12.2% 
vs. 6.6%), have higher BMI (32.7±6.9 vs. 29.3±5.4), and have chronic kidney disease (13.7% 
vs. 4.6%), a history of heart failure (19.7% vs. 13.3%), lung disease (14.4% vs. 11.3%) and 
prior myocardial infarction (32.0% vs. 27.0%). They also more commonly had lower 
baseline (13.1±1.6 g/dL vs. 14.0±1.5 g/dL) and nadir hemoglobin (12.3±1.7 g/dL vs. 
13.0±1.6 g/dL), and have undergone prior PCI (48.4% vs. 36.3%).   
Bleeding Outcomes 
In unadjusted analyses, patients with DM had lower reported bleeding over the year 
following PCI using the BARC ≥1 classification (DM vs. no DM: BARC ≥1: 77.7% vs. 
87.6%, p<0.001), but not when using the BARC ≥2 classification (BARC ≥ 2: 4.5% vs. 
5.3%, p=0.375). In adjusted analysis, patients with DM had lower odds of BARC ≥1 
bleeding during follow-up. After adjusting for demographic and clinical factors, patients with 
DM had lower odds of BARC ≥1 bleeding during follow-up (odds ratio [OR] 0.50, 95% CI 
0.38-0.66) as compared with patients who did not have DM. When excluding bruising from 
BARC ≥1 classification, the observed association persisted (OR 0.77, 95% CI 0.62-0.96; 
Figure 5). This decreased risk of bleeding in DM did not vary by PCI indication (ACS vs. 
elective; p-interaction=0.324). 
Subsequently, we performed a sensitivity analysis to explore bleeding incidence at 
follow up after excluding bruising from the definition of bleeding (i.e. BARC ≥1 minus 
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bruising as the primary outcome). This analysis yielded lower bleeding outcomes in patients 
with DM, as compared with without DM (OR 0.77, 95% CI 0.62-0.96; Figure 5). 
We completed a second sensitivity analysis assessing crude bleeding rates (BARC ≥1 
including bruising) at 1,6 and 12 months, including all patients discharged on DAPT, without 
excluding patients who were not on DAPT at 12 month follow up. In patients with DM, there 
was no difference in the odds of reporting bleeding at 1 month. However, patients with DM 
had lower odds of reporting bleeding at 6 months (OR 0.53, 95% CI 0.42-0.67) and 12 
months (OR 0.65, 95% CI 0.52-0.81). The crude bleeding rates were not statistically different 
at 1-month follow up between patients with and without DM, but they were lower at 6 and 
12-month follow up (65.1% vs. 73.4%, p<0.001 and 77.7% vs. 87.6%, p<0.001 in patients 
with vs. without DM at 6 and 12 months, respectively).  
Table 2. Adjusted odds of ≥BARC 1 bleeding in patients with diabetes on long term dual 
anti platelet therapy during the year following percutaneous coronary intervention  
 
 Odds Ratio (95% Confidence Interval) 
≥ BARC 1 bleeding BARC ≥ 1, excluding bruising 
Diabetes (vs. no DM) 0.50 (0.38-0.66) 0.77 (0.62-0.96) 
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* Most severe level of bleeding reported 
* For multivariable adjustment, the following covariates were used: Age, gender, race, BMI, history of CKD, 
acute coronary syndrome at time of presentation, heart failure and chronic lung disease, history of prior PCI 
and/or MI, bleeding and/or transfusion during index hospitalization, and index PCI admission lab values 
including platelets and nadir hemoglobin 
Abbreviations: BMI: body mass index; CKD: chronic kidney disease; PCI: percutaneous intervention; MI: 
myocardial infarction 
Figure 4.  Bleeding outcomes over the year following PCI in patients with and without 
diabetes mellitus  
 
 
Dual Anti platelet Therapy Discontinuance 
The rate of DAPT discontinuation was similar between patients with and without DM 
at one-year follow up (13.6% vs. 14.2% respectively, p=0.719). For patients not on a 
thienopyridine or aspirin at follow up, a follow up question regarding reason for 
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discontinuance of the medication was asked. The reasons provided by patients for 
discontinuance are referenced in Supplemental Table 2.   
All statistical analyses performed using SPSS version 22 and syntax is referenced in 
Supplemental Figure 1.  
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CHAPTER 4 
DISCUSSION 
In the multicenter, contemporary PRISM registry, among patients who underwent 
PCI and were discharged and maintained on DAPT, we found that patients with DM had 
lower bleeding rates over the year following PCI when compared with patients who did not 
have DM. To our knowledge, this is the first study to compare the incidence of bleeding 
following PCI in patients with and without DM and to examine the independent association 
of DM with bleeding events, adjusting for relevant clinical and socioeconomic factors. In 
addition, we examined bleeding outcomes according to indication for PCI (i.e. acute 
coronary syndrome [emergent or urgent] versus elective indication) and found that results 
were consistent regardless of the bleeding definition and persisted despite adjustment for 
multiple potential confounders and in multiple sensitivity analyses.  
Prior Studies 
Our study supports and extends the prior literature, which has been primarily limited 
to sub-studies of clinical trials.18,19 These results advance knowledge by highlighting the 
independent association of DM with bleeding outcomes, an area that was not previously 
explored. The OPS/PRISM registry provided a unique cohort for investigation of our 
research questions by including rich documentation of patient characteristics and clinical 
variables from representative US centers, promoting the external generalizability of our 
findings. Our results of less bleeding with DAPT among those patients with DM demonstrate 
that the risk-benefit balance of prolonged DAPT may be even more favorable than previously 
recognized in this group of patients.  
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In the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet 
Inhibition with Prasugrel—Thrombolysis in Myocardial Infarction (TRITON TIMI-38), 
patients with a myocardial infarction treated with PCI were randomized to DAPT with 
prasugrel vs. clopidogrel. In pre-specified subgroup analyses, major bleeding rates (2.6% vs. 
2.0%) and major or minor bleeding rates (4.8% vs. 4.2%) were similar between subjects with 
and without DM, respectively. However, patients with DM did not experience a significant 
increase in bleeding with more aggressive platelet inhibition (i.e., prasugrel vs. clopidogrel), 
in contrast with the bleeding outcomes among patients without DM.20 As a result, the net 
clinical benefit of prasugrel compared with clopidogrel was greater in patients with DM, 
compared with patients without DM.20  In contrast to the results of TRITON-TIMI 38, the 
results of the PLATelet inhibition and patient Outcomes (PLATO) study, which randomized 
patients following acute coronary syndrome to DAPT with ticagrelor vs. clopidogrel, showed 
that the rates of major bleeding not related to bypass surgery were higher in patients with vs. 
without DM (5.2% vs. 3.8%) with no differential effect of ticagrelor vs. clopidogrel on either 
ischemic or bleeding outcomes. Both of these large clinical trials examined bleeding 
outcomes in patients admitted for acute coronary syndrome, while our study enrolled a 
broader range of indications for PCI, including, but not limited to, acute coronary syndrome.  
Some of the differences between our results and those from the 2 trials above, likely 
result from the bleeding definitions used (TRITON and PLATO trials classified bleeding 
events within major and minor categories), as we found no difference between rates of 
BARC ≥2 bleeding between groups. Another important distinction lies in that our study 
represented a real-world cohort, including patients who otherwise are not eligible for or 
choose to participate in clinical trials. As such, we believe that our study substantially 
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expands the current understanding of the bleeding outcomes, and the risk-benefit balance, of 
long-term DAPT in this important patient group. 
Potential Mechanisms for Lower Bleeding Outcomes 
The results of lower bleeding rates with DAPT use in PCI patients with DM vs. those 
who did not have DM could be explained by increased platelet reactivity in the setting of 
hyperglycemia and insulin resistance,27,28 thereby exposing patients with DM to a higher risk 
of ischemic events and a lower risk of bleeding while receiving long-term DAPT.  
Additionally, although we adjusted for body mass index in our multivariable model, obesity 
has been described to attenuate bleeding,29 and could therefore in part explain improved 
bleeding outcomes in patients with DM (who are more commonly overweight or obese). 
Future studies are therefore needed to elucidate whether or not bleeding outcomes are related 
in a “dose-dependent” fashion to level of glycemic control in patients with DM. This 
information could further our understanding of the level of platelet inhibition in diabetic 
patients with suboptimal glycemic control, as compared with those who are euglycemic.  
Clinical Implications 
Appropriate patient selection for prolonged DAPT is critically important, as one must 
weigh the additional ischemic benefits against the risks of bleeding that are associated with 
DAPT. This risk-benefit balance was recently highlighted by the Dual Antiplatelet Therapy 
(DAPT) trial, in which prolonged DAPT for 30 vs. 12 months after DES implantation led to 
reduced ischemic outcomes but more bleeding.30 Ideally, patients who are selected for 
prolonged DAPT should be those at higher risk of recurrent thrombotic events and who also 
have a lower risk of bleeding. In many situations, such as advanced age, the factors that 
increase ischemic risk also increase bleeding risk, making the decision to prescribe prolonged 
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DAPT more challenging. In the setting of DM, the ischemic benefits of prolonged DAPT are 
well-established—both in terms of DES use (which requires longer DAPT vs. BMS) for 
reduction of restenosis and for greater absolute risk reduction of general ischemic events, 
such as stent thrombosis and myocardial infarction. Collectively, these data reinforce the 
preferential use of DES over BMS in patients with DM by supplementing the well-known 
greater absolute risk reduction in restenosis in patients with DM by also defining a lower risk 
of bleeding, the adverse consequence of using DES and prolonged DAPT. 
Our findings are also meaningful in the context of patient counseling as they may 
inform shared decision making choices between patient and provider ahead of the PCI 
procedure. Given this information, patients with DM may better understand their odds of 
adverse events following a common and necessary therapy.  
Our findings of less bleeding with DAPT among those patients with DM demonstrate 
that the risk-benefit balance of prolonged DAPT may be even more favorable than previously 
recognized. Accordingly, future studies are needed to replicate these findings in an acute 
coronary syndrome and elective PCI cohort. In addition, future investigations should be 
conducted to elucidate the impact of glycemic control on bleeding outcomes in patients with 
DM. Lastly, examining the type of anti platelet medication prescribed would allow us to 
examine the association of use of particular anti platelet agents with bleeding with more 
granularity.  
Limitations 
Our findings should be considered in the context of several potential limitations. First, 
bleeding events were self-reported, which may have led to over- or under-estimation of 
bleeding events. However, the presence of DM would not be expected to lead to differential 
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reporting bias.  Second, DAPT adherence was also self-reported, as we did not have access to 
pharmacy data to verify the exact duration of DAPT use. Lastly, due to the observational 
nature of our study, there is the possibility of residual confounding despite extensive 
adjustment. Such potential confounders may include markers of DM control, which were not 
collected in our registry. Measurement of hemoglobin A1c (a marker of average DM) control 
over the 2-3 months preceding A1c analysis), insulin use and presence of microalbuminuria 
may have informed our understanding of the gradation of bleeding outcomes based on strata 
of DM control. Another potential confounder that was not captured in our database was 
hemoglobin measurement at follow up. This value could have potentially extended our 
ability to validate patient self-report of bleeding events during the follow up period. Last, 
there is a potential that patients may have discontinued DAPT or dropped out of the study 
due to bleeding episodes. Differential DAPT discontinuance between patients with and 
without DM due to bleeding events may have skewed our observed bleeding rates to over- or 
under- estimate bleeding outcomes.   
Conclusions 
In this real-world PCI registry, patients with DM experienced significantly lower risk 
of bleeding on long-term DAPT than those without DM over the year following index PCI. 
As patients with DM also derive greater ischemic benefit from DES, which require prolonged 
DAPT, our findings suggest that the balance between benefit and risk of this therapeutic 
approach is likely even more favorable in patients with DM than previously described.  
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APPENDIX 
Table A-1: Baseline characteristics of patients with and without diabetes in the OPS/PRISM registry 
  
Overall 
n=2270 
Diabetes 
n=737 
No Diabetes 
n=1533 
P -Value 
Mean age (years) 64.3 ± 10.5 64.9±9.8 64.1±10.9 0.099 
Male gender 72.3% 68.1% 74.3% 0.002 
White race 91.6% 87.8% 93.4% <0.001 
No insurance 2.6% 1.9% 2.9% 0.187 
Completed high school  91.8% 90.6% 92.3% 0.152 
Married 68.2% 64.0% 70.1% 0.004 
Never smoker 45.8% 46.0% 45.8% 0.007 
Insurance for medication  97.4% 98.1% 97.1% 0.187 
Avoided care due to cost 
(past 12M) 
20.2% 21.4% 19.6% 0.860 
Mean BMI 30.4 ± 6.1 32.7±6.9 29.3±5.4 <0.001 
Chronic kidney disease 7.6% 13.7% 4.6% <0.001 
Mean platelet count pre-PCI 
(x1000) 
217.4 ± 63.2 216.7±63.2 217.7±63.3 0.723 
Thrombocytopenia** 0.8% 1.6% 0.5% 0.010 
Bleeding problems* (BL) 5.7% 5.5% 5.8% 0.743 
Mean Hemoglobin 13.7 ± 1.6 13.1±1.6 14.0±1.5 <0.001 
Mean Hemoglobin nadir 12.8 ± 1.7 12.3±1.7 13.0±1.6 <0.001 
Prior heart failure 13.3% 19.7% 10.2% <0.001 
RBC/ Whole Blood 
Transfusion  
1.5% 1.9% 1.3% 0.324 
Chronic lung disease 11.3% 14.4% 9.8% 0.001 
Prior PCI 40.2% 48.4% 36.3% <0.001 
Prior MI 27.0% 32.0% 24.5% <0.001 
Anticoagulation  5.2% 6.0% 4.8% 0.223 
In hospital bleed┼ 2.1% 1.8% 2.2% 0.477 
Abbreviations: BMI: body mass index; BL: baseline; RBC: red blood cell; PCI: percutaneous intervention; MI: myocardial 
infarction 
*Defined as answering in the affirmative to the following questionnaire question: Do you have bleeding problems, such as 
blood in your urine, blood in your stool, coughing up blood or vomiting blood, or an ulcer? 
**Defined as platelet count <100 
┼Defined as greater than or equal to a 2 g/dL drop in hemoglobin 
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Table A-2: The Bleeding Academic Research Consortium definition for bleeding 
 
•No bleedingBARC 0
•Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of 
studies, hospitalization, or treatment by a healthcare professional
•May include episodes leading to self-discontinuation of medical therapy by the patient without 
consulting a healthcare professional
BARC 1
•Any overt, actionable sign of hemorrhage (eg, more bleeding than would be expected for a clinical 
circumstance, including bleeding found by imaging alone) that does not fit the criteria for type 3, 4, 
or 5 but does meet at least one of the following criteria:
•requires nonsurgical, medical intervention by a healthcare professional 
•leads to hospitalization/increased level of care/prompting evaluation
BARC 2
•3a: Overt bleeding plus hemoglobin drop of 3 to <5 g/dL* (provided hemoglobin drop is related to bleed); any 
transfusion with overt bleeding
•3b: Overt bleeding plus hemoglobin drop ≥5 g/dL*(provided hemoglobin drop is related to bleed); cardiac 
tamponade; bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid); 
bleeding requiring intravenous vasoactive agents
•3c: Intracranial hemorrhage (does not include microbleeds or hemorrhagic transformation, does include 
intraspinal); subcategories confirmed by autopsy or imaging or lumbar puncture; intraocular bleed 
compromising vision
BARC 3
•Perioperative intracranial bleeding within 48 h
•Reoperation after closure of sternotomy for the purpose of controlling bleeding
•Transfusion of ≥5 U whole blood or packed red blood cells within a 48-h period†
•Chest tube output ≥2L within a 24-h period
BARC 4 
•5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious
•5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmationBARC 5
 
 
28 
 
Table A-3.  Sites participating in the OPS-PRISM registries  
Medical Center Location Principal Investigator 
*Mid America Heart Institute Kansas City, MO John Spertus, MD 
Kaiser Permanente San Francisco, CA Ed McNulty, MD 
*Integris Heart Hospital Oklahoma City, OK Charles Bethea, MD 
*Mayo Clinic Rochester, MN Henry Ting, MD 
Henry Ford Hospital Detroit, MI Mayra Guerrero, MD 
Baylor Health Plano Heart 
Hospital 
Plano, TX Bradley Leonard, MD 
Bay State Medical Center Springfield, MA Aaron Kugelmass, MD 
*Yale New Haven Hospital New Haven, CT Jeptha Curtis, MD 
Prairie Heart St. John’s 
Hospital 
Springfield, IL Mark Shelton, MD 
Washington University 
Barnes-Jewish Hospital 
Saint Louis, MO Richard Bach, MD 
*Sites that participated in both OPS and PRISM registries  
 
 
Table A-4.  List of reasons for DAPT discontinuance  
“I was never told to take it” 
“I was told to take it only for a specified time” 
“My doctor told me to stop” 
“I stopped on my own because of cost” 
“I stopped on my own because of side effects” 
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Table A-5.  Baseline characteristics of patients missing vs. not missing 12-month data  
  
Missing 1 year data 
n=482 
Not missing 
1 year data 
n=2270 
P -Value 
Age (years) 60.9±12.8 64.3±10.5 <0.001 
Male gender 69.7% 72.3% 0.253 
White race 86.0% 91.6% <0.001 
No insurance 6.7% 2.6% <0.001 
Completed high school  88.5% 91.8% 0.022 
Married 57.8% 68.2% <0.001 
Never smoker 33.6% 45.8% <0.001 
Insurance for medication  90.0% 93.8% 0.003 
Avoided care due to cost 
(past 12M) 
27.2% 20.2% <0.001 
BMI 31.0±7.0 30.4±6.1 0.064 
Chronic kidney disease 11.8% 7.6% 0.002 
Platelet count pre-PCI 
(x1000) 
226.8±66.1 217.4±63.2 0.004 
Thrombocytopenia 0.9% 0.8% 1.000 
Bleeding problems* (BL) 8.4% 5.7% 0.027 
Hemoglobin 13.5±1.9 13.7±1.6 0.008 
Hemoglobin nadir 12.5±1.9 12.8±1.7 <0.001 
Prior heart failure 9.5% 6.8% 0.034 
RBC/ Whole Blood 
Transfusion  
1.1% 1.5% 0.554 
Chronic lung disease 17.0% 11.3% <0.001 
Prior PCI 45.0% 40.2% 0.052 
Prior MI 32.2% 27.0% 0.021 
Anticoagulation   7.1%  7.2% 0.096 
In hospital bleed┼ 2.7% 2.1% 0.392 
Drug eluting stent  71.2% 86.1% <0.001 
*Defined as answering in the affirmative to the following questionnaire question: Do you have bleeding problems, such as 
blood in your urine, blood in your stool, coughing up blood or vomiting blood, or an ulcer?  
**Defined as platelet count <100 
┼Defined as greater than or equal to a 2 g/dL drop in hemoglobin 
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Figure A-1 
SPSS Program Syntax delineating code for creation of baseline characteristics table, logistic 
regression models for primary and sensitivity analyses, and discontinuance rates stratified by diabetes 
status 
CROSSTABS 
  /TABLES=BARC1Plus_1 BARC1Plus_6 BARC1Plus_y Barc1PlusDC_y Barc2PlusDC_y BY 
Diabetes 
  /FORMAT=AVALUE TABLES 
  /STATISTICS=CHISQ  
  /CELLS=COUNT ROW COLUMN TOTAL  
  /COUNT ROUND CELL. 
CROSSTABS 
  /TABLES=BARC1Plus_1 BARC1Plus_6 BARC1Plus_y Barc1PlusDC_y Barc2PlusDC_y BY 
Diabetes 
  /FORMAT=AVALUE TABLES 
  /STATISTICS=CHISQ  
  /CELLS=COUNT EXPECTED ROW COLUMN TOTAL  
  /COUNT ROUND CELL. 
T-TEST GROUPS=Diabetes(0 1) 
  /MISSING=ANALYSIS 
  /VARIABLES=Age BodyMassIndex hgb_nadir Hemoglobin 
  /CRITERIA=CI(.95). 
FREQUENCIES VARIABLES=Age BodyMassIndex Hemoglobin hgb_nadir 
  /STATISTICS=MINIMUM MAXIMUM SKEWNESS SESKEW KURTOSIS SEKURT 
  /HISTOGRAM NORMAL 
  /ORDER=ANALYSIS. 
EXAMINE VARIABLES=Age BodyMassIndex Hemoglobin hgb_nadir BY Diabetes 
  /PLOT BOXPLOT STEMLEAF HISTOGRAM NPPLOT 
  /COMPARE GROUPS 
  /STATISTICS DESCRIPTIVES 
  /CINTERVAL 95 
  /MISSING LISTWISE 
  /NOTOTAL. 
 
T-TEST GROUPS=Diabetes(0 1) 
  /MISSING=ANALYSIS 
  /VARIABLES=Sex Race RaceWhite InsuranceNone Married Smokingstatus PriorMI PriorPCI 
Chronicheart  
    Chronickidney Chroniclung BodyMassIndex Heartfailure AspirinonDischarge Thienopyridine  
    Insuranceformedications BleedingproblemsBL Avoidedcareduetocost 
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Completedhighschooleducation  
    PlateletcountprePCI Cardiogenicshockprecath DES RBCwholebloodtransfusion ACS Inhospital  
    HeartFailure_A BARC1Plus_1 BARC1Plus_6 BARC1Plus_y Barc1PlusDC_y Barc2PlusDC_y 
Thrombocytopenia  
    anticoag_d 
  /CRITERIA=CI(.95). 
 
*************Now going to compare nonparametrically distributed continuous variables at 
baseline between patients with and without DM********************** 
DATASET ACTIVATE DataSet1. 
*Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (Age BodyMassIndex Hemoglobin hgb_nadir) GROUP (Diabetes)  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE 
  /CRITERIA ALPHA=0.05  CILEVEL=95. 
 
*Nonparametric Tests: Independent Samples.  
NPTESTS  
  /INDEPENDENT TEST (Age BodyMassIndex Hemoglobin hgb_nadir) GROUP (Diabetes)  
  /MISSING SCOPE=ANALYSIS USERMISSING=EXCLUDE 
  /CRITERIA ALPHA=0.05  CILEVEL=95. 
 
DESCRIPTIVES VARIABLES=Age BodyMassIndex hgb_nadir Hemoglobin 
  /STATISTICS=MEAN STDDEV MIN MAX. 
 
**********checking logistic regression initial output********** 
 
LOGISTIC REGRESSION VARIABLES Barc1PlusDC_y 
  /METHOD=ENTER ACS PlateletcountprePCI Chronickidney PriorPCI Smokingstatus  
  /CONTRAST (ACS)=Indicator 
  /CONTRAST (Chronickidney)=Indicator 
  /CONTRAST (PriorPCI)=Indicator 
  /CONTRAST (Smokingstatus)=Indicator 
  /PRINT=CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
 
*****************checking assumptions for logistic regression modeling (sample size is adequate, 
no multicollinearity, no unexplained outliers**************** 
 
REGRESSION 
  /MISSING PAIRWISE 
  /STATISTICS COEFF OUTS R ANOVA COLLIN TOL 
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  /CRITERIA=PIN(.05) POUT(.10) 
  /NOORIGIN  
  /DEPENDENT BARC1Plus_y 
  /METHOD=ENTER Age Sex RaceWhite BodyMassIndex Chronicheart Chronickidney 
Chroniclung  
    BleedingproblemsBL Hemoglobin PlateletcountprePCI RBCwholebloodtransfusion Inhospital  
    Thrombocytopenia anticoag_d PriorPCI PriorMI 
  /CASEWISE PLOT(ZRESID) OUTLIERS(3). 
 
REGRESSION 
  /MISSING PAIRWISE 
  /STATISTICS COEFF OUTS R ANOVA COLLIN TOL 
  /CRITERIA=PIN(.05) POUT(.10) 
  /NOORIGIN  
  /DEPENDENT BARC1Plus_y 
  /METHOD=ENTER Age Sex RaceWhite BodyMassIndex Chronicheart Chronickidney 
Chroniclung  
    BleedingproblemsBL Hemoglobin PlateletcountprePCI RBCwholebloodtransfusion Inhospital  
    Thrombocytopenia anticoag_d PriorPCI PriorMI 
  /SCATTERPLOT=(*ZRESID ,*ZPRED) 
  /RESIDUALS NORMPROB(ZRESID) 
  /CASEWISE PLOT(ZRESID) OUTLIERS(3). 
 
***********multicollinearity not violated, sample size adequate, this is the logistic regression 
model looking at primary outcome at 1 year of BARC greater than or equal to 1 bleeding 
INCLUDING bruising************ 
 
LOGISTIC REGRESSION VARIABLES BARC1Plus_y 
  /METHOD=ENTER Chronickidney PriorPCI BleedingproblemsBL Hemoglobin 
RBCwholebloodtransfusion  
    Inhospital Thrombocytopenia anticoag_d Heartfailure Chroniclung PriorMI Age Sex RaceWhite  
    BodyMassIndex  
  /CONTRAST (Chronickidney)=Indicator(1) 
  /CONTRAST (PriorPCI)=Indicator(1) 
  /CONTRAST (BleedingproblemsBL)=Indicator(1) 
  /CONTRAST (Inhospital)=Indicator(1) 
  /CONTRAST (Thrombocytopenia)=Indicator(1) 
  /CONTRAST (anticoag_d)=Indicator(1) 
  /CONTRAST (Heartfailure)=Indicator(1) 
  /CONTRAST (Chroniclung)=Indicator(1) 
  /CONTRAST (PriorMI)=Indicator(1) 
  /CONTRAST (Sex)=Indicator(1) 
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  /CONTRAST (RaceWhite)=Indicator(1) 
  /CLASSPLOT 
  /CASEWISE OUTLIER(2) 
  /PRINT=GOODFIT ITER(1) CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
 
*****************logistic regression (producing odds ratios) for first sensitivity analysis, looking 
at BARC greater than or equal to 1, EXCLUDING bruising, at 1 year)************** 
 
LOGISTIC REGRESSION VARIABLES Barc1PlusDC_y 
  /METHOD=ENTER Chronickidney PriorPCI BleedingproblemsBL Hemoglobin 
RBCwholebloodtransfusion  
    Inhospital Thrombocytopenia anticoag_d Heartfailure Chroniclung PriorMI Age Sex RaceWhite  
    BodyMassIndex Diabetes  
  /CONTRAST (Chronickidney)=Indicator(1) 
  /CONTRAST (PriorPCI)=Indicator(1) 
  /CONTRAST (BleedingproblemsBL)=Indicator(1) 
  /CONTRAST (Inhospital)=Indicator(1) 
  /CONTRAST (Thrombocytopenia)=Indicator(1) 
  /CONTRAST (anticoag_d)=Indicator(1) 
  /CONTRAST (Heartfailure)=Indicator(1) 
  /CONTRAST (Chroniclung)=Indicator(1) 
  /CONTRAST (PriorMI)=Indicator(1) 
  /CONTRAST (Sex)=Indicator(1) 
  /CONTRAST (RaceWhite)=Indicator(1) 
  /CLASSPLOT 
  /CASEWISE OUTLIER(2) 
  /PRINT=GOODFIT ITER(1) CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
 
***********logistic regression model looking at BARC 2 or greater at 1 year*************** 
 
LOGISTIC REGRESSION VARIABLES Barc2PlusDC_y 
  /METHOD=ENTER Chronickidney PriorPCI BleedingproblemsBL Hemoglobin 
RBCwholebloodtransfusion  
    Inhospital Thrombocytopenia anticoag_d Heartfailure Chroniclung PriorMI Age Sex RaceWhite  
    BodyMassIndex Diabetes  
  /CONTRAST (Chronickidney)=Indicator(1) 
  /CONTRAST (PriorPCI)=Indicator(1) 
  /CONTRAST (BleedingproblemsBL)=Indicator(1) 
  /CONTRAST (Inhospital)=Indicator(1) 
  /CONTRAST (Thrombocytopenia)=Indicator(1) 
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  /CONTRAST (anticoag_d)=Indicator(1) 
  /CONTRAST (Heartfailure)=Indicator(1) 
  /CONTRAST (Chroniclung)=Indicator(1) 
  /CONTRAST (PriorMI)=Indicator(1) 
  /CONTRAST (Sex)=Indicator(1) 
  /CONTRAST (RaceWhite)=Indicator(1) 
  /CLASSPLOT 
  /CASEWISE OUTLIER(2) 
  /PRINT=GOODFIT ITER(1) CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
 
***********************logistic regression sensitivity analyses looking at BARC greater than or 
equal to 1 including bruising at 1 and 6 months, not requiring them to be on DAPT at 1 and 6 
months)********* 
 
LOGISTIC REGRESSION VARIABLES BARC1Plus_1 
  /METHOD=ENTER Chronickidney PriorPCI BleedingproblemsBL Hemoglobin 
RBCwholebloodtransfusion  
    Inhospital Thrombocytopenia anticoag_d Heartfailure Chroniclung PriorMI Age Sex RaceWhite  
    BodyMassIndex Diabetes  
  /CONTRAST (Chronickidney)=Indicator(1) 
  /CONTRAST (PriorPCI)=Indicator(1) 
  /CONTRAST (BleedingproblemsBL)=Indicator(1) 
  /CONTRAST (Inhospital)=Indicator(1) 
  /CONTRAST (Thrombocytopenia)=Indicator(1) 
  /CONTRAST (anticoag_d)=Indicator(1) 
  /CONTRAST (Heartfailure)=Indicator(1) 
  /CONTRAST (Chroniclung)=Indicator(1) 
  /CONTRAST (PriorMI)=Indicator(1) 
  /CONTRAST (Sex)=Indicator(1) 
  /CONTRAST (RaceWhite)=Indicator(1) 
  /CLASSPLOT 
  /CASEWISE OUTLIER(2) 
  /PRINT=GOODFIT ITER(1) CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
 
LOGISTIC REGRESSION VARIABLES BARC1Plus_6 
  /METHOD=ENTER Chronickidney PriorPCI BleedingproblemsBL Hemoglobin 
RBCwholebloodtransfusion  
    Inhospital Thrombocytopenia anticoag_d Heartfailure Chroniclung PriorMI Age Sex RaceWhite  
    BodyMassIndex Diabetes  
  /CONTRAST (Chronickidney)=Indicator(1) 
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  /CONTRAST (PriorPCI)=Indicator(1) 
  /CONTRAST (BleedingproblemsBL)=Indicator(1) 
  /CONTRAST (Inhospital)=Indicator(1) 
  /CONTRAST (Thrombocytopenia)=Indicator(1) 
  /CONTRAST (anticoag_d)=Indicator(1) 
  /CONTRAST (Heartfailure)=Indicator(1) 
  /CONTRAST (Chroniclung)=Indicator(1) 
  /CONTRAST (PriorMI)=Indicator(1) 
  /CONTRAST (Sex)=Indicator(1) 
  /CONTRAST (RaceWhite)=Indicator(1) 
  /CLASSPLOT 
  /CASEWISE OUTLIER(2) 
  /PRINT=GOODFIT ITER(1) CI(95) 
  /CRITERIA=PIN(0.05) POUT(0.10) ITERATE(20) CUT(0.5). 
 
***********checking DAPT discontinuance rates (by 12 months) in patients with and without DM 
discharged on DAPT*********************** 
 
CROSSTABS 
  /TABLES=Discontinuance BY diabetes 
  /FORMAT=AVALUE TABLES 
  /STATISTICS=CHISQ  
  /CELLS=COUNT 
  /COUNT ROUND CELL. 
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